GPC-3 show different behaviors among different cancers, while it has been reported to be downregulated in breast cancer, ovarian cancer and lung adenocarcinoma (40), it has been reported to be upregulated in HCC (41). Here, GPC3 is linked to hepatocellular carcinoma.